Cargando…

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) are uncommon in non-small cell lung cancer (NSCLC). These mutations are generally resistant to first-generation EGFR tyrosine kinase inhibitors, unlike common EGFR mutations, including exon 19 del...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Naohiro, Horio, Yoshitsugu, Fujiwara, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816854/ https://www.ncbi.nlm.nih.gov/pubmed/36618815 http://dx.doi.org/10.21037/atm-2022-56

Ejemplares similares

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Wang, Fenfang, et al.
Publicado: (2020)

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
por: Vyse, Simon, et al.
Publicado: (2019)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
por: Murano, Chihiro, et al.
Publicado: (2019)

Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
por: Low, Jia Li, et al.
Publicado: (2023)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
por: Chen, Jianxin, et al.
Publicado: (2022)

Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
por: Tamirat, Mahlet Z., et al.
Publicado: (2021)

EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
por: Pacini, Laura, et al.
Publicado: (2022)

Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
por: Wang, Jun, et al.
Publicado: (2022)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
por: Byeon, Seonggyu, et al.
Publicado: (2019)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
por: Pan, Binyang, et al.
Publicado: (2023)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang, Shannon S, et al.
Publicado: (2021)

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
por: Wang, Mengzhao, et al.
Publicado: (2022)

Not All EGFR Exon 20 Insertions Are Created Equal
por: Lin, Yen-Ting, et al.
Publicado: (2020)

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
por: Shah, Vishal, et al.
Publicado: (2023)

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
por: Brazel, Danielle, et al.
Publicado: (2022)

Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with EGFR exon 20 insertion mutations
por: Wang, Lifeng, et al.
Publicado: (2022)

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
por: Kian, Waleed, et al.
Publicado: (2022)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
por: Le, Xiuning, et al.
Publicado: (2022)

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
por: Gao, Xin, et al.
Publicado: (2020)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
por: Shi, Chao, et al.
Publicado: (2022)

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib
por: Chen, Yan, et al.
Publicado: (2022)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
por: Morita, Chie, et al.
Publicado: (2021)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
por: Pacini, Laura, et al.
Publicado: (2021)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
por: Nishino, Masaya, et al.
Publicado: (2021)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study
por: Xu, Chun-Wei, et al.
Publicado: (2020)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
por: Prelaj, Arsela, et al.
Publicado: (2022)

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
por: Li, Kelly, et al.
Publicado: (2023)

Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
por: Zhang, Mai, et al.
Publicado: (2023)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u4gfg5jhq821bfu1hfechnc2rl